. Author manuscript; available in PMC: 2019 Nov 20.

Published in final edited form as: Am Soc Clin Oncol Educ Book. 2018 May 23;38:330–341. doi: 10.1200/EDBK_201215

TABLE 2.

Results of the CABOSUN Trial: Cabozantinib Versus Sunitinib in First-Line mRCC, With Outcomes by Subgroup Analysis Including IMDC Risk Group and Presence of Bone Metastases

Outcome	CABO (79 Patients)	SUN (78 Patients)	HR (95% CI)	p Value

Confirmed ORR, % (95% CI)	46 (34–57)	18(10–28)

Median PFS, months (95% CI)	8.2 (6.2–8.8)	5.6 (3.4–8.1)	0.66 (0.46–0.95)	.012

Bone metastases	6.14	3.38	0.54 (0.31–0.95)

Poor IMDC risk	6.14	2.77	0.75 (0.35–1.65)

Intermediate risk	8.31	6.24	0.64 (0.43–0.96)

Median OS, months (95% CI)	30.3 (14.6–35)	21.8 (16.3–27)	0.8 (0.50–1.26)

Abbreviations: mRCC, metastatic renal cell carcinoma; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; HR, hazard ratio; ORR, objective response rate; PFS, progression-free survival; OS, overall survival.